← Eichor
Study identifier: NCT05104788 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer  ·  Sponsor: Peking University Cancer Hospital & Institute

PhasePhase 2
Planned participants27
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

This description comes directly from the study's public registry record.

Talk to the study team

NAN Wu, M.D.  ·  8613466692698  ·  nanwu@bjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

BeijingCancerHBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05104788